Formulation and Evaluation of Sustained Release Matrix Tablets Containing Ambroxol Hydrochloride

Abstract

The evolution of pharmaceutical drug delivery systems has witnessed a shift towards novel technologies, replacing conventional dosage forms with innovative approaches. Among these advancements, oral administration remains paramount due to its patient acceptance, ease of use, and cost-effectiveness. However, conventional dosage forms often necessitate frequent dosing, leading to fluctuating blood levels and potential therapeutic failures or toxicities. Sustained release formulations emerge as a solution to this challenge, offering prolonged and controlled drug release to maintain therapeutic levels over time. This study focuses on formulating sustained release matrix tablets of Ambroxol HCl, a mucolytic agent used in respiratory conditions. By utilizing polymers like HPMC K100M and HPMC 5CPS, the aim is to develop tablets capable of sustaining drug release, thereby improving patient compliance and therapeutic outcomes. The significance lies in addressing the therapeutic relevance of Ambroxol hydrochloride by providing a consistent dosage regimen. Evaluation of these matrix tablets will contribute to advancing drug delivery systems, optimizing treatment efficacy, and enhancing patient care.